Italian Acute Stroke Study-Hemodilution "IASS-H"


Phase 3 Results


Intention-to- treat analysis failed to show any differences in neurologic deficit, mortality, or neurologic disability among the groups. Efficacy analysis showed a significantly higher degree of neurologic improvement in GM1 group patients compared with patients in the placebo group during the first 15 days. These differences were no longer statistically significant at Day 120.